Related Experiment Video

Updated: Jun 18, 2026

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors
12:40

A Method for Screening and Validation of Resistant Mutations Against Kinase Inhibitors

Published on: December 7, 2014

JAK2-V617F mutation in Moroccan patients with myeloproliferative disorders: contribution, diagnosis and therapeutic

A Benmoussa1, H Dehbi, S Fehri

  • 1Laboratory of Genetics and Molecular Pathologies, Faculty of Medicine, Casablanca, Morocco. benmamal@hotmail.com

Pathologie-Biologie
|November 27, 2009
PubMed
Abstract

Insights

The JAK2 V617F mutation is prevalent in Moroccan myeloproliferative disorder (MPD) patients, particularly in polycythemia vera. This study is the first to investigate JAK2 V617F mutation status in Moroccan MPD patients.

Area of Science:

  • Hematology
  • Molecular Biology
  • Oncology

Background:

  • The JAK2 V617F mutation is a key factor in myeloproliferative disorders (MPDs).
  • Its role in MPD pathogenesis is established.
  • The mutation's prevalence in Morocco was previously unstudied.

Purpose of the Study:

  • To determine the frequency of the JAK2 V617F mutation in Moroccan patients with non-chronic myeloid leukemia (CML) MPDs.
  • To analyze the mutation's association with specific MPD subtypes and clinical features.

Main Methods:

  • A cohort of 70 Moroccan patients with non-CML MPDs was analyzed.
  • JAK2 V617F mutation detection was performed using allele-specific PCR (AS-PCR).

Main Results:

  • JAK2 V617F mutation incidence was 89.47% in polycythemia vera, 62.5% in essential thrombocythemia, and 33.33% in idiopathic myelofibrosis.
  • The mutation was absent in patients with secondary erythrocytosis or thrombocytosis.
  • Mutation-positive patients exhibited higher hemoglobin, hematocrit, and white blood cell counts.

Conclusions:

  • This study provides the first data on JAK2 V617F mutation status in Moroccan MPD patients.
  • The findings support the JAK2 V617F mutation's significance in MPDs, excluding BCR/ABL-negative myeloid malignancies.
  • Further research is warranted to understand the mutation's full impact in the Moroccan population.

More Related Videos

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm08:12

Transduction-Transplantation Mouse Model of Myeloproliferative Neoplasm

Published on: December 22, 2016

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells12:04

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells

Published on: March 10, 2023

Related Concept Videos

Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
Leishmaniasis01:30

Leishmaniasis

Leishmaniasis is a protozoal disease caused by species of the genus Leishmania and transmitted through the bite of infected female sandflies. The parasite exists in two principal morphological forms during its life cycle. A sandfly acquires intracellular amastigotes from an infected reservoir host, such as a dog. Within the sandfly, these forms differentiate into motile, flagellated promastigotes. During a subsequent blood meal, promastigotes are injected into the human host, where they...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...